LungLifeAI Logo
Menu
close

News & Updates

Our Purpose:
To be a driving force in the early detection of lung cancer.

October 1, 2020

LungLife AI, with Collaborators from Mount Sinai and MD Anderson, to Present Clinical Data on Liquid Biopsy Test for Early Lung Cancer Detection

Thousand Oaks, CA – October 1, 2020 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that clinical data from a research collaboration in early lung cancer detection will be presented at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting taking place on October 2nd […]
• Read More
December 23, 2019

LungLife AI Receives CLIA certification for its Cancer Diagnostic Laboratory

LungLife AI the developer of an Artificial Intelligence (AI) enabled non-invasive liquid biopsy test for the early detection of lung cancer, announced today that the Company has received certification from the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Under the “deemed status” provision of the US Department of Health and Human Services (HHS) Center for […]
• Read More
1 … 6 7 8

Investor inquiries

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down